/ /

  • linkedin
  • Increase Font
  • Sharebar

    FDA approves one-of-a-kind IOL with extended range of vision

     

    The randomized clinical trial involved 148 cataract patients implanted with the new IOL, while 151 were implanted with the monofocal IOL.

    The study evaluated VA at near, intermediate, and far ranges, contrast sensitivity, and adverse events for 6 months after implantation.

    More: Treating presbyopia with an eye drop?

    Of the patients implanted with the novel IOL, 77% had 20/25 vision, without glasses at intermediate distances, compared to 34% in the monofocal group.

    For near distances, patients in the treatment group were able to read two additional, progressively smaller lines on a standard eye chart compared with the monofocal group.

    Blog: 3 habits for successful time management

    Both patient groups had comparable results for good distance vision.

    The indication of the lens is for adult patients with less than 1.0 D of pre-existing corneal astigmatism who have had cataract surgery.

    More to come

    “The large amount of clinical data that we had before the US study was even completed…has been very consistent, demonstrating increased depth-of-focus...and low levels of visual symptoms,” said Tom Frinzi, senior vice president, Abbott Medical Optics.

    The extended depth-of-focus IOL is expected to be available by September, but it may not be long before the company introduces another product to the ophthalmic community.

    "One of the things that attracted me to AMO earlier this year was the robustness and richness of our pipeline. We have a lot of exciting products under development both on the cataract and refractive side,” he said. “We’re going to keep trying to have a steady cadence of new product introductions. As Frank Sinatra once said, 'The best is yet to come.'"

    Learn more about the FDA's latest approval for Shire's dry eye drug!

     

    Related articles:

    More about the new generation presbyopia-correcting IOL

    Keys to finding the ideal mix-and-match IOL strategy

    How IOL platform designs are achieving quality of vision

    Jolie Higazi
    Jolie is the Content Specialist for Ophthalmology Times. She can be reached at [email protected]

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results